Uterine ( DrugBank: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 118 | Myelomeningocele | 1 |
| 280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 1 |
| 288 | Autoimmune acquired coagulation factor deficiency | 1 |
118. Myelomeningocele
Clinical trials : 10 / Drugs : 18 - (DrugBank : 7) / Drug target genes : 8 - Drug target pathways : 12
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04362592 (ClinicalTrials.gov) | November 2, 2018 | 24/3/2020 | In-Utero Endoscopic Correction of Spina Bifida | In-Utero Endoscopic Correction of Spina Bifida: Laparotomy or Percutaneous | Neural Tube Defects;Spina Bifida;Myelomeningocele | Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique;Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique | University of Southern California | NULL | Recruiting | 18 Years | 52 Years | Female | 33 | N/A | United States |
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 25 / Drugs : 29 - (DrugBank : 15) / Drug target genes : 14 - Drug target pathways : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048193 | 2021-07-01 | 2021-07-04 | Clinical study of bilateral uterine artery embolization versus surgical resection in the treatment of uterine arteriovenous malformation | Clinical study of bilateral uterine artery embolization versus surgical resection in the treatment of uterine arteriovenous malformation | Uterine arteriovenous malformation | Experimental group:Uterine arterial embolization;Control group:Surgical resection; | Henan Provincial People's Hospital | NULL | Pending | Female | Experimental group:10;Control group:10; | Phase 4 | China |
288. Autoimmune acquired coagulation factor deficiency
Clinical trials : 205 / Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03871764 (ClinicalTrials.gov) | December 1, 2015 | 8/3/2019 | Prediction of Outcome in Severe Preeclampsia | Relation of 3rd Trimester Uterine Artery Doppler Flow Velocimetry Indices, Factor V Leiden Mutation and Placental Pathology to the Severity of Preeclampsia | Leiden Factor V Deficiency,Preeclampsia;Doppler Examination;Palental Pathology | Diagnostic Test: blood sample , doppler of uterine vessel and placenta | Cairo University | NULL | Completed | N/A | N/A | Female | 100 | NULL |